ClinicalTrials.gg

Program

Prazosin

Also written as “Prazosin HCl”, “Prazosin HCl 2mg” and “Prazosin HCl 1 mg”.

Its studies are mostly in Hypertension · Stress Disorders, Post-Traumatic, led by 3 companies.

Furthest: phase 3, since Jul 8, 20214 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer20 open or runningphase 1since Jul 8, 2021Jul 8, 2021none ahead
Haffkine Bio-Pharmaceutical10 open or runningphase 3since Sep 14, 2008Sep 14, 2008none ahead
Otsuka10 open or runningphase 1since Oct 22, 2021Oct 22, 2021none ahead

Also a collaborator on its studies: iqvia-pty-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 14, 2008First study: phase 3 study in Scorpion StingsNew to Haffkine Bio-PharmaceuticalHaffkine Bio-Pharmaceutical · NCT00753064 · 81 enrolled · India
  2. Jul 8, 2021Pfizer's first study: phase 1 study in HypertensionNew to PfizerPfizer · NCT04967443 · 72 enrolled · United States
  3. Oct 22, 2021Otsuka's first study: phase 1 study in Stress Disorders, Post-TraumaticNew to OtsukaOtsuka · NCT05189977 · 34 enrolled · United States
  4. Nov 13, 2025Phase 1 study in HealthyPfizer · NCT07231978 · 69 enrolled · Belgium

TargetBeta

“Adrenergic receptor alpha-1 antagonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
TamsulosinruleBoehringer Ingelheimphase 460
OxymetazolineruleAbbViephase 420
Phentolamineruleopus-genetics-incphase 418
Epinephrinerulenasus-pharmaphase 417
MidodrineruleTakedaphase 410

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07231978Healthy · Belgium1CompletedPfizerApr 3, 202669
NCT05189977Stress Disorders, Post-Traumatic · United States1TerminatedOtsukaAug 3, 202334
NCT04967443Hypertension · United States1CompletedPfizerFeb 15, 202272
NCT00753064Scorpion Stings · India3CompletedHaffkine Bio-PharmaceuticalDec 200781

How it is read

Names in the registry

  • “Prazosin HCl”, 1 entry
  • “Prazosin HCl 2mg”, 1 entry
  • “Prazosin HCl 1 mg”, 1 entry
  • “Prazosin”, 1 entry
  • “AScVS + Prazosin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.